Regulatory Affairs
FDA 21 CFR Part 211 vs. EU GMP Annex 1: Key Differences
A comprehensive breakdown of the core differences between US FDA 21 CFR Part 211 and EU GMP Annex 1 for sterile and non-sterile pharmaceutical manufacturing.
Regulatory Affairs
CAPA vs. Root Cause Analysis (RCA) in Pharma
Understanding the critical distinction between Root Cause Analysis (RCA) and Corrective and Preventive Actions (CAPA) in pharmaceutical quality management systems.
Regulatory Affairs
AQL vs. RQL: Choosing the Right Sampling Plan
A technical guide to understanding Acceptable Quality Limit (AQL) versus Rejectable Quality Limit (RQL) in pharmaceutical statistical sampling and batch release.
Regulatory Affairs
The Digital-First Regulatory Landscape: How Ireland's Life Science Sector Is Adapting to the EU AI Act, EHDS, and Governance by Design
A comprehensive guide for Irish pharmaceutical, MedTech, and life science professionals on the EU AI Act implementation, the European Health Data Space, cGMP compliance in an AI-driven environment, ALCOA+ in digital systems, and the practical steps organisations must take to achieve governance by design in 2026.